The Cooper Companies, Inc. (NASDAQ:COO) Shares Sold by Royal Bank of Canada

Royal Bank of Canada lessened its holdings in The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 21.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 475,423 shares of the medical device company's stock after selling 129,675 shares during the period. Royal Bank of Canada owned approximately 0.24% of Cooper Companies worth $43,705,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of COO. Byrne Asset Management LLC purchased a new position in Cooper Companies during the fourth quarter worth $33,000. OFI Invest Asset Management purchased a new position in Cooper Companies during the fourth quarter worth $34,000. New Age Alpha Advisors LLC purchased a new position in Cooper Companies during the fourth quarter worth $38,000. Covestor Ltd boosted its stake in Cooper Companies by 35.5% during the fourth quarter. Covestor Ltd now owns 458 shares of the medical device company's stock worth $42,000 after buying an additional 120 shares during the period. Finally, Atala Financial Inc purchased a new position in Cooper Companies during the fourth quarter worth $51,000. Institutional investors own 24.39% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on COO. Robert W. Baird lowered their target price on shares of Cooper Companies from $117.00 to $107.00 and set an "outperform" rating for the company in a research note on Friday, March 7th. Citigroup lowered their target price on shares of Cooper Companies from $115.00 to $110.00 and set a "buy" rating for the company in a research note on Friday, March 7th. JPMorgan Chase & Co. lowered their target price on shares of Cooper Companies from $120.00 to $110.00 and set an "overweight" rating for the company in a research note on Friday, March 7th. Wall Street Zen raised shares of Cooper Companies from a "hold" rating to a "buy" rating in a research note on Wednesday. Finally, Piper Sandler reissued an "overweight" rating and set a $115.00 target price (down from $120.00) on shares of Cooper Companies in a research note on Friday, March 7th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $110.25.

Cooper Companies Stock Down 0.6%

Shares of COO stock traded down $0.47 on Friday, hitting $78.83. The stock had a trading volume of 1,548,951 shares, compared to its average volume of 1,493,548. The company has a quick ratio of 1.12, a current ratio of 1.91 and a debt-to-equity ratio of 0.32. The business has a 50 day moving average price of $80.25 and a 200 day moving average price of $89.34. The company has a market cap of $15.76 billion, a PE ratio of 40.43, a P/E/G ratio of 2.25 and a beta of 1.08. The Cooper Companies, Inc. has a one year low of $69.81 and a one year high of $112.38.

Cooper Companies (NASDAQ:COO - Get Free Report) last released its quarterly earnings data on Thursday, March 6th. The medical device company reported $0.92 earnings per share for the quarter, meeting the consensus estimate of $0.92. The firm had revenue of $964.70 million during the quarter, compared to the consensus estimate of $981.25 million. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. Research analysts anticipate that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.